APHA:NSD-Tilray, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 17.23

Change

0.00 (0.00)%

Market Cap

USD 6.86B

Volume

0.01B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

Tilray, Inc (APHA) Stock Analysis:
Based on the Tilray, Inc stock forecasts from 0 analysts, the average analyst target price for Tilray, Inc is not available over the next 12 months. Tilray, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Tilray, Inc is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Tilray, Inc’s stock price was USD 17.23. Tilray, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +31.83% over the last year.

About

Tilray Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The company offers cannabis-lifestyle and consumer packaged goods; and hemp-based foods and alcoholic beverages. It offers medical cannabis in extracts and dried f ...Read More

Company Website : http://www.tilray.com

Address : 98 Talbot Street West, Leamington, ON, Canada, N8H 1M8

Employees : 1,200

Fiscal Year End : May

Currency: USD

Country : USA

Technical Indicators

Beta : 2.62

52 Week High : 32.29

Short Ratio : 1.91

52 Week Low : 11.88

Shorted Shares : 26,549,484

200 Day Moving Average : 15.21

Shorted Shares Previous Month : 15,981,428

50 Day Moving Average : 17.56

Shares Held By Insiders : 0.11%

Short Percentage : 8.53%

Shares Held by Institutions : 19.08%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-1.67 (-2.24%)

 USD7.07B 16.40 37.25
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

-1.60 (-3.97%)

 USD3.83B N/A N/A
CGC Canopy Growth Corporation

-0.14 (-1.80%)

 USD3.31B N/A N/A
TLRY Tilray Inc

-0.32 (-5.09%)

 USD3.20B N/A N/A
PCRX Pacira BioSciences Inc

+0.38 (+0.59%)

 USD2.85B 47.07 19.70
IRWD Ironwood Pharmaceuticals Inc

+0.25 (+2.29%)

 USD1.92B 3.61 7.38
SUPN Supernus Pharmaceuticals Inc

-0.10 (-0.34%)

 USD1.56B 19.40 9.45
DVAX Dynavax Technologies Corporati..

N/A

 USD1.53B N/A 98.57

ETFs Containing APHA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 31.83% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.83% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 80.61% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.61% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 158.58% N/A N/A N/A N/A
Risk Adjusted Return 50.83% N/A N/A N/A N/A
Market Capitalization 6.86B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.60 N/A N/A N/A N/A
Price/Book Ratio 5.61 N/A N/A N/A N/A
Price / Cash Flow Ratio -51.30 N/A N/A N/A N/A
EV/EBITDA 454.68 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -34.14% N/A N/A N/A N/A
Return on Invested Capital -2.80% N/A N/A N/A N/A
Return on Assets -1.31% N/A N/A N/A N/A
Debt to Equity Ratio 22.09% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.91 N/A N/A N/A N/A
Short Percent 8.53% N/A N/A N/A N/A
Beta 2.62 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.